Individualized Treatment and Sequencing in Multiple Myeloma

Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss individualized treatment selection and sequencing in multiple myeloma as increasingly effective therapies expand available options. Dr. Baljevic emphasizes balancing efficacy with safety, feasibility, convenience, cost, access, treatment adherence, and quality of life, noting that treatment decisions should reflect both clinical evidence and individual patient preferences. The experts also consider how limited-duration therapy may change long-term management, including the role of MRD assessment and other monitoring strategies following treatment discontinuation. Dr. Baljevic highlights the possibility of durable treatment-free remission and the emerging concept of cure for a subset of patients with multiple myeloma. Dr. Kapoor notes that sequencing remains challenging because of limited comparative data, while emerging studies of bispecific-based approaches continue to produce increasingly deep responses. The discussion highlights MajesTEC-5 and MajesTEC-4 data and considers how treatment de-escalation and discontinuation may become increasingly relevant as clinicians seek to maintain disease control while reducing treatment burden.